Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose fasting bioequivalence of linagliptin tablets (Mylan vs Trazenta) in healthy Japanese volunteers
jRCT2071260058Phase 1Completed
- Sponsor
- Viatris
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Viatris. Primary endpoint: Pivotal fasting bioequivalence. Started Oct 2025; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2071260058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260058.